cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Prelude Therapeutics Inc
2 own
4 watching
Current Price
$7.14
$0.08
(1.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
341.63M
52-Week High
52-Week High
10.72
52-Week Low
52-Week Low
3.87
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization341.63M
icon52-Week High10.72
icon52-Week Low3.87
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Prelude Therapeutics Inc do?
Prelude Therapeutics Inc is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Inc was incorporated under the laws of the State of Delaware in February 2016. Our principal executive offices are located at 200 Powder Mill Road, Wilmington, DE 19803, and our telephone number is (302) 467-1280. Our website address is www.preludetx.com.
Read More
How much money does Prelude Therapeutics Inc make?
News & Events about Prelude Therapeutics Inc.
Market News Video
5 months ago
In trading on Thursday, shares of Prelude Therapeutics Inc (PRLD) crossed below their 200 day moving average of 8.33, changing hands as low as 8.19 per share. Prelude Therapeutics Inc shares are currently trading off about 3.9% on the day...
Globe Newswire
6 months ago
Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 are on track for the second half of 2022 ...
Globe Newswire
11 months ago
WILMINGTON, Del., March 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the Barclays 2022 Global Healthcare Conference in Miami, ...
Zolmax
11 months ago
Credit Suisse AG purchased a new stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD Get Rating) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 6,950 shares of the companys stock, valued at ...
Benzinga
11 months ago
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Prelude Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Prelude Therapeutics Inc shares?
plus_minus_icon
How can I buy Prelude Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Prelude Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Prelude Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Prelude Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Prelude Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Prelude Therapeutics Inc?
plus_minus_icon
What percentage is Prelude Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Prelude Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$7.14
$0.08
(1.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00